rational for her3-targeting in nrg1 fusion-positive nsclc
Published 9 months ago • 118 plays • Length 0:34Download video MP4
Download video MP3
Similar videos
-
12:49
nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
-
2:43
nrg1 fusions: treatment options - targeted therapies in lung cancer 2023
-
1:21
phase iii trial of denosumab for breast cancer risk reduction in brca1 carriers
-
1:49
adcs for lung cancer
-
7:18
caris life sciences partnering with merus to detect neuregulin 1 (nrg1) fusions in cancer patients
-
1:14
prognostic value of beta-2 adrenergic receptor levels in her2 breast cancer
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
5:42
ros1 nsclc: diagnosing and treatment - 2022 program: targeted therapies forum
-
0:42
hpn328, a tri-specific t-cell engager, in sclc and neuroendocrine cancers
-
6:20
scientific rationale for development of trk inhibitors
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
1:45
diagnosing g3 nets and necs
-
1:04
aacr 2023 highlights in pi3kα and fgfr inhibition
-
41:36
resiliency: covid-19 stress and nf
-
3:08
tamoxifen's role in triple-negative breast cancer
-
3:41
rationales for repeat molecular testing
-
3:49
unmet needs in r/r her2 metastatic breast cancer
-
5:24
resilience chapter 3 - treatment
-
4:16
rescuer: resistance under combinatorial treatment in er and er- breast cancer